CharlesLouisWisemanMDFACP, QME

Oncology • Beverly Hills, CA

Founder and Director, Briacell Therapeutics Corp

Join to view full profile

Dr. Wiseman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wiseman's full profile

Already have an account?

Office
8900 Wilshire Blvd, Second Floor
Beverly Hills, CA 90211
Phone+1 323-377-4741

Fax+1 626-577-9069

Education & Training

University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1975 - 1976
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterResidency, Hematology and Medical Oncology, 1972 - 1973
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1970 - 1972
University of Utah HealthInternship, Transitional Year, 1969 - 1970
David Geffen School of Medicine at UCLAClass of 1969

Certifications & Licensure

CA State Medical License 1971 - 2026
FL State Medical License 2016 - 2018
TX State Medical License 1973 - 1980
LA State Medical License 1974 - 1975

Awards, Honors, & Recognition

Founder and Director BriaCell Therapeutics, 2014-2016

Clinical Trials

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer Start of enrollment: 1991 Apr 01
Completed
Phase 2
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers Start of enrollment: 2004 Nov 01
Terminated
Phase 1, Phase 2

Publications & Presentations

PubMed

9 citations
Objective Clinical Regression of Metastatic Breast Cancer in Disparate Sites after Use of Whole-Cell Vaccine Genetically Modified to Release Sargramostim
Charles Wiseman, Alex Kharazi
The Breast Journal. 2006-09-01
236 citations
A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth
Lisette G de Pillis, Ami Radunskaya, Charles L. Wiseman
Cancer Research. 2005-09-01
13 citations
Phorbol myristate acetate and Bryostatin 1 rescue IFN-gamma inducibility of MHC class II molecules in LS1034 colorectal carcinoma cell line.
Yuri Kudinov, Charles Wiseman, A. I. Kharazi
Cancer Cell International. 2003-03-25

Press Mentions

With Pandemic in Rearview Mirror, BriaCell Charges Ahead with Cancer ImmunotherapyApril 24th, 2023
BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) MeetingMay 29th, 2020
BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson HealthFebruary 11th, 2020
Join now to see all